The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe

被引：18

作者：

Kowalska, Justyna D. ^{[1
]}

Kase, Kerstin ^{[2
]}

Vassilenko, Anna ^{[3
]}

Harxhi, Arjan ^{[4
]}

Lakatos, Botond ^{[5
]}

Lukic, Gordana Dragovic ^{[6
]}

Verhaz, Antonija ^{[7
,8
]}

Yancheva, Nina ^{[9
]}

Dumitrescu, Florentina ^{[10
]}

Jilich, David ^{[11
,12
]}

Machala, Ladislav ^{[12
,13
]}

Skrzat-Klapaczynska, Agata ^{[1
]}

Matulionyte, Raimonda ^{[14
]}

机构：

[1] Med Univ Warsaw, Hosp Infect Dis, Dept Adults Infect Dis, Warsaw, Poland

[2] West Tallinn Cent Hosp, Tallinn, Estonia

[3] Belarusian State Med Univ, Minsk, BELARUS

[4] Univ Hosp Ctr Tirana, Infect Dis Serv, Tirana, Albania

[5] South Pest Cent Hosp, Natl Inst Hematol & Infect Dis, Natl Ctr HIV, Budapest, Hungary

[6] Univ Belgrade, Sch Med, Dept Pharmacol Clin Pharmacol & Toxicol, Belgrade, Serbia

[7] Univ Clin Ctr Republ Srpska, Clin Infect Dis, Banja Luka, Bosnia & Herceg

[8] Univ Banja Luka, Dept Infect Dis, Fac Med, Banja Luka, Bosnia & Herceg

[9] Specialized Hosp Act Treatment Infect & Parasi, Dept AIDS, Sofia, Bulgaria

[10] Univ Med & Pharm Craiova, Craiova, Romania

[11] Charles Univ Prague, Fac Med 1, Dept Infect Dis, Prague, Czech Republic

[12] Bulovce Hosp, Prague, Czech Republic

[13] Charles Univ Prague, Dept Infect Dis, Fac Med 3, Prague, Czech Republic

[14] Vilnius Univ, Inst Clin Med, Dept Infect Dis & Dermatovenerol, Fac Med, Vilnius, Lithuania

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 104卷

关键词：

HIV; SARS-CoV-2; COVID-19; Antiretroviral therapy; Protease inhibitors; INFECTED PERSONS;

D O I：

10.1016/j.ijid.2020.12.026

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: There is currently no evidence suggesting that COVID-19 takes a different course in HIV-positive patients on antiretroviral treatment compared to the general population. However, little is known about the relation between specific HIV-related factors and the severity of the COVID-19 disease. Methods: We performed a retrospective analysis of cases collected through an on-line survey distributed by the Euroguidelines in Central and Eastern Europe Network Group. In statistical analyses characteristics of HIV-positive patients, asymptomatic/moderate and moderate/severe course were compared. Results: In total 34 HIV-positive patients diagnosed with COVID-19 were reported by 12 countries (Estonia, Czech Republic, Lithuania, Albania, Belarus, Romania, Serbia, Bosnia and Herzegovina, Poland, Russia, Hungary, Bulgaria). Asymptomatic courses of COVID-19 were reported in four (12%) cases, 11 (32%) patients presented with mild disease not requiring hospitalization, moderate disease with respiratory and/or systemic symptoms was observed in 14 (41%) cases, and severe disease with respiratory failure was found in five (15%) patients. The HIV-related characteristics of patients with an asymptomatic/mild course of COVID-19 were comparable to those with a moderate/severe course of COVID-19, except for the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in cART regimen (0.0% vs. 31.6% respectively, p = 0.0239). Conclusions: In our analyses HIV viral suppression and immunological status were not associated with the course of COVID-19 disease. On the contrary the cART regimen could contribute to severity of SARS-CoV-2 infection. Large and prospective studies are necessary to further investigate this relationship. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：293 / 296

页数：4

共 46 条

[41] Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study
Li, Yan
Hu, Zhengyuan
Guo, Yufei
Zhao, Zheng
Li, Kunpeng
Wang, Xiuru
Zhang, Jie
Liang, Dongfeng
Zhang, Jianglin
Hu, Xiaoyue
Zhu, Jian
Huang, Feng
[J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
[42] COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al
Gianfrancesco, Milena
Hyrich, Kimme L.
Yazdany, Jinoos
Machado, Pedro M.
Robinson, Philip C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10)
[43] Analysis of 160 nonhospitalized COVID-19 patients with mild to moderate symptoms from an Austrian general medical practice: from typical disease pattern to unexpected clinical featuresUntersuchung von 160 nichthospitalisierten COVID-19-Patienten mit mildem bis mittelschwerem Verlauf aus einer österreichischen Allgemeinarztpraxis: vom typischen Krankheitsmuster bis zu unerwarteten klinischen Merkmalen
Carina Bouwensch
Viktoria Hahn
Florence Boulmé
[J]. Wiener Medizinische Wochenschrift, 2022, 172 : 198 - 210
[44] A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial
Takayama, Shin
Namiki, Takao
Ito, Takashi
Arita, Ryutaro
Nakae, Hajime
Kobayashi, Seiichi
Yoshino, Tetsuhiro
Ishigami, Tomoaki
Tanaka, Koichiro
Kainuma, Mosaburo
Nochioka, Kotaro
Takagi, Airi
Mimura, Masaru
Yamaguchi, Takuhiro
Ishii, Tadashi
[J]. TRIALS, 2020, 21 (01)
[45] A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial
Shin Takayama
Takao Namiki
Takashi Ito
Ryutaro Arita
Hajime Nakae
Seiichi Kobayashi
Tetsuhiro Yoshino
Tomoaki Ishigami
Koichiro Tanaka
Mosaburo Kainuma
Kotaro Nochioka
Airi Takagi
Masaru Mimura
Takuhiro Yamaguchi
Tadashi Ishii
[J]. Trials, 21
[46] During an ongoing pandemic of severe acute respiratory syndrome coronavirus 2, main question which has arisen in everyone's mind is about the immune response that may protect from reinfection. Coronaviruses are known for short-term immunity. Their ability of mutations enables them to escape host immunity, thus increasing chances of reinfection. Here we report two cases of reinfection among health care workers who presented with symptoms of COVID-19 disease, after 3 months of first infectious course. Such documentations are necessary for epidemiological purposes and also to monitor response of virus on re-exposure. © 2021 The Authors. Published by Elsevier Ltd.
Ahmed, A.
Sana, F.
Ikram, A.
Yousaf, S.
Khan, A.
[J]. NEW MICROBES AND NEW INFECTIONS, 2021, 42

← 1 2 3 4 5 →